From Financial Modeling Prep: 2025-02-12 12:39:00

Biogen (NASDAQ:BIIB) beat Q4 2024 earnings expectations with $3.44 EPS and $2.5 billion revenue, up 3% year-over-year. However, shares dropped over 4% on a lackluster 2025 outlook. The company projects adjusted EPS of $15.25-$16.25, barely meeting consensus, with total revenue declining by a mid-single-digit percentage due to MS portfolio weakness.

Despite challenges, Biogen sees new product launches driving growth. Alzheimer’s treatment LEQEMBI generated $87 million in Q4 sales, $50 million from the U.S. market. Rare disease portfolio showed momentum, with SKYCLARYS contributing $102 million in revenue. The market remains cautious about near-term headwinds, especially MS revenue declines.



Read more at Financial Modeling Prep:: Biogen Shares Fall 4% as Weak Outlook Overshadows …